IQVIA Holdings Inc. $IQV Shares Purchased by PGGM Investments

Key Points

• PGGM Investments increased its stake in IQVIA Holdings Inc. by 115.2% during the second quarter, owning approximately $31.3 million worth of the stock.
• IQVIA's stock recently traded at $189.96, with a market cap of $32.29 billion and a debt-to-equity ratio of 2.45.
• The company reported quarterly earnings of $2.81 EPS, exceeding estimates, and has set its FY 2025 guidance at 11.750-12.050 EPS.

PGGM Investments boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 115.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 198,698 shares of the medical research company's stock after purchasing an additional 106,347 shares during the quarter. PGGM Investments owned approximately 0.11% of IQVIA worth $31,313,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IQVIA by 83.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,861 shares of the medical research company's stock valued at $1,938,000 after acquiring an additional 4,483 shares during the period. Wellington Management Group LLP boosted its holdings in shares of IQVIA by 12.7% during the fourth quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company's stock valued at $1,924,000 after acquiring an additional 1,106 shares during the period. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 129.5% during the first quarter. Versant Capital Management Inc now owns 677 shares of the medical research company's stock valued at $119,000 after acquiring an additional 382 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of IQVIA by 27,448.4% during the first quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock valued at $68,286,000 after acquiring an additional 385,925 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Up 5.1%

IQVIA stock opened at $189.96 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $32.29 billion, a price-to-earnings ratio of 27.49, a price-to-earnings-growth ratio of 1.98 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.34. The firm's 50 day moving average price is $187.49 and its two-hundred day moving average price is $167.18.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Truist Financial boosted their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Robert W. Baird boosted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. UBS Group boosted their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 price objective on shares of IQVIA in a report on Wednesday, September 3rd. Eighteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $229.64.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.